Lupin has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (US FDA) for its facility in Goa, India, with a satisfactory Voluntary Action Indicated (VAI) classification. The EIR was issued following an inspection of the facility from November 10 to November 21, 2025. Nilesh Gupta, Managing Director, Lupin, stated, �We are pleased to have received the EIR with a VAI classification from the US FDA for our Goa facility. This outcome reflects our continued focus on quality excellence and regulatory compliance, reinforcing our commitment to delivering safe and effective medicines to patients worldwide.�Powered by Capital Market - Live News

Lupin has received approval from the U.S. FDA for its Abbreviated New Drug Application (ANDA) for Brivaracetam Oral Solution 10 mg/mL. Brivaracetam is the bioequivalent to Briviact� Oral Solution, 10 mg/mL, of UCB, Inc. and is indicated for the treatment of partial-onset seizures in patients 1 month of age and older. Following the approval, the company initiated the launch of Brivaracetam Oral Solution in the United States. Brivaracetam Oral Solution (RLD Briviact) had an estimated annual sale of USD 135 million in the U.S. (IQVIA MAT December 2025). Powered by Capital Market - Live News

Lupin has received the approval from European Commission for its biosimilar ranibizumab, RanluspecTM (for vials and pre-filled syringes), following the recent positive opinion from the Committee for Medicinal Products for Human Use.Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds and inhibits vascular endothelial growth factor A. Its indications encompass the treatment of patients with neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, proliferative diabetic retinopathy, and choroidal neovascularization. Lupin`s biosimilar ranibizumab will be commercialized by Sandoz across the European Union (excluding Germany). In France, the product will be commercialized by two companies, Sandoz and Biogaran. Powered by Capital Market - Live News

Lupin has allotted 75,273 equity shares under ESOP on 13 February 2026. In view of the above, the issued and paid-up share capital of the Company has increased to Rs 91,40,86,438 consisting of 45,70,43,219 equity shares of Rs 2/- each.Powered by Capital Market - Live News

Net profit of Lupin rose 37.47% to Rs 1175.55 crore in the quarter ended December 2025 as against Rs 855.16 crore during the previous quarter ended December 2024. Sales rose 26.37% to Rs 7100.45 crore in the quarter ended December 2025 as against Rs 5618.56 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales7100.455618.56 26 OPM %31.8624.13 - PBDT2261.571342.72 68 PBT1948.611071.27 82 NP1175.55855.16 37 Powered by Capital Market - Live News